Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP3 | O14638 | 3/20 | 0.50 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | BCR | P11274 | 1/20 | 0.39 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31156949 | 1.00 | ENPP3 (0.50) | ENPP3ENPP1MAPTMEN1KMT2A | |
| SCHEMBL1249967 | 0.86 | ENPP3 (0.48) | ENPP3ENPP1MAPTMEN1KMT2A | |
| SCHEMBL29606592 | 0.80 | ENPP3 (0.54) | ENPP3ENPP1MAPTMEN1KMT2A | |
| SCHEMBL1272465 | 0.80 | OPRD1 (0.45) | ENPP3ENPP1MAPTMEN1KMT2A | |
| SCHEMBL1713486 | 0.78 | L3MBTL1 (0.61) | ENPP3ENPP1MEN1KMT2AL3MBTL1 | |
| SCHEMBL17581423 | 0.78 | SLC9A1 (0.44) | ENPP3ENPP1MAPTMEN1KMT2A | |
| SCHEMBL18211693 | 0.78 | MAPT (0.40) | MAPTMEN1KMT2AL3MBTL1NR1H2 | |
| SCHEMBL22669487 | 0.77 | MAPT (0.43) | MAPTMEN1KMT2ANR1H2NR1H3 | |
| SCHEMBL30280392 | 0.76 | ENPP3 (0.48) | ENPP3ENPP1MAPTMEN1KMT2A | |
| SCHEMBL30298892 | 0.76 | MAPT (0.43) | MAPTMEN1KMT2AL3MBTL1NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160326162-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2016-11-10 | — | — | US | disclosed |
| US-20160326162-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2016-11-10 | — | — | US | disclosed |
| WO-2016164641-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2016-10-13 | — | — | WO | disclosed |
| US-9326987-B2 | Indazole derivatives for use in the treatment of influenza virus infection | GLAXO GROUP LIMITED (GB) | 2016-05-03 | — | — | US | disclosed |
| US-9326987-B2 | Indazole derivatives for use in the treatment of influenza virus infection | GLAXO GROUP LIMITED (GB) | 2016-05-03 | — | — | US | disclosed |
| US-9326987-B2 | Indazole derivatives for use in the treatment of influenza virus infection | GLAXO GROUP LIMITED (GB) | 2016-05-03 | — | — | US | disclosed |
| US-20130165433-A1 | Novel Use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-06-27 | — | — | US | disclosed |
| US-20130165433-A1 | Novel Use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-06-27 | — | — | US | disclosed |
| US-20130165433-A1 | Novel Use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-06-27 | — | — | US | disclosed |
| US-20120245171-A1 | BENZPYRAZOLE DERIVATIVES AS INHIBITORS OF PI3 KINASES | GLAXO GROUP LIMITED (GB) | 2012-09-27 | — | — | US | disclosed |
| US-20120245171-A1 | BENZPYRAZOLE DERIVATIVES AS INHIBITORS OF PI3 KINASES | GLAXO GROUP LIMITED (GB) | 2012-09-27 | — | — | US | disclosed |
| US-20120245171-A1 | BENZPYRAZOLE DERIVATIVES AS INHIBITORS OF PI3 KINASES | GLAXO GROUP LIMITED (GB) | 2012-09-27 | — | — | US | disclosed |
| US-20120238559-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-09-20 | — | — | US | disclosed |
| US-20120238559-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-09-20 | — | — | US | disclosed |
| US-20120238559-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-09-20 | — | — | US | disclosed |
| WO-2012032065-A1 | INDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF INFLUENZA VIRUS INFECTION | GLAXO GROUP LIMITED (GB) | 2012-03-15 | — | — | WO | disclosed |
| WO-2011067364-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011067365-A1 | BENZPYRAZOLE DERIVATIVES AS INHIBITORS OF P13 KINASES | GLAXO GROUP LIMITED (GB) | 2011-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165433-A1 | Novel Use | HAVCR2, MAVS, ENTPD5 | ENPP3 276/4885ENPP1 382/4885MAPT 3121/4885 |
| US-20120238559-A1 | NOVEL COMPOUNDS | PIK3CA, PIK3CD, PIK3C2B | ENPP3 869/4885ENPP1 620/4885MAPT 2143/4885 |
| US-20120245171-A1 | BENZPYRAZOLE DERIVATIVES AS INHIBITORS OF PI3 KINASES | PIK3C3, PIK3CA, PIK3CD | ENPP3 698/4885ENPP1 816/4885MAPT 2733/4885 |
| US-20160326162-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K11, MAP4K2, PLK1 | ENPP3 3678/4885ENPP1 3067/4885MAPT 631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.